AstraZeneca has formed a collaboration with the Lupus Research Alliance and its clinical research affiliate, Lupus Therapeutics, to support clinical trials and patient recruitment across the drugmaker’s lupus development programs. The agreement includes support for conducting studies, raising awareness of trials and educating healthcare professionals and patients.
Lupus Therapeutics oversees the Lupus Clinical Investigators Network, which brings together clinical researchers across North America. The collaboration will draw on that network for clinical research and will include peer-to-peer support and early education as part of its patient engagement efforts.
Lupus Therapeutics and the network will support BLOSSOM, a pediatric trial of anifrolumab-fnia, a type I interferon receptor antagonist. They will also work with AstraZeneca on several therapies in early clinical development for systemic lupus erythematosus and lupus nephritis, including a CAR-T cell therapy targeting CD19 and BCMA. The collaboration covers two T-cell engager trials: TITAN, which evaluates a CD8-guided CD20 T-cell engager, and ASSURO, which evaluates a bispecific CD19 T-cell engager.
The agreement builds on earlier work between AstraZeneca and the alliance that helped lay the groundwork for anifrolumab-fnia’s initial approval. The alliance funded research that identified a set of genes activated by type I interferons in people with lupus, and AstraZeneca led the drug’s subsequent development.
Lupus is a chronic autoimmune disease that can affect the kidneys, brain, heart, lungs and skin, as well as the blood and joints. About 90% of people with lupus are women, and the disease is most often diagnosed between ages 15 and 45.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!